Pason specializes in the early screening, diagnosis, and concomitant diagnosis of neurodegenerative diseases, cancers, infectious diseases, and new drug development. We are the exclusive distributor of Fujirebio's neurology products in China and have always been dedicated to the early screening, diagnosis, and prognosis evaluation of neurodegenerative diseases, cancers, and infectious diseases. Pason also provides clinicians, researchers, and the industry with various high-quality technical services, including training, GLP new drug study, testing for research samples, new technology and product validation, technical consultation, etc.

The AUTO-LIPA instrument and Inno-LiPA (Inno-Lia) reagents can detect HPV, HBV, HCV, HIV, etc. ELISA platform and INNOTEST reagents can make accurate diagnostics on neurodegenerative diseases, cancers and infectious diseases. LUMIPULSE instruments and reagents can detect biomarkers related to neurodegenerative diseases in cerebrospinal fluid and plasma samples. After a long time of clinical use in Europe and North America, iterative updating of both the instruments and reagents, and repeated validation experiments in three continents, the combination of FUJIREBIO's instruments and the new generation reagents provides the customers with the advantages of full automation, simple operation experience, high sensitivity, high stability, and accurate results. CSF and plasma samples can be tested directly on the instruments without pre-processing. The entire diagnostic procedure is fully automated, and the influence of the operators on the experimental results is excluded to the maximum extent.